Screener
Aclaris Therapeutics ACRS Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's shares (diluted)?
- Aclaris Therapeutics (ACRS) reported shares (diluted) of 142.7M in Q2 2026.
- How has Aclaris Therapeutics's shares (diluted) changed year-over-year?
- Aclaris Therapeutics's shares (diluted) increased by 16.4% year-over-year, from 122.6M to 142.7M.
- What is the long-term trend for Aclaris Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's shares (diluted) has grown at a 21.9% compound annual growth rate (CAGR), from 222.3M to 490.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Aclaris Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude